IgG4-related sclerosing cholangitis

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

No FDA or trial events recorded yet for IgG4-related sclerosing cholangitis.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

Patient Assistance Programs1

WEGOVY

Novo Nordisk

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

1 FDA-approved

WEGOVY

(SEMAGLUTIDE)standard

Novo Nordisk

GLP-1 Receptor Agonist [EPC]

12.1 Mechanism of Action Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that ...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for IgG4-related sclerosing cholangitis.
Search all trials →
Search clinical trials for IgG4-related sclerosing cholangitis

Recent News & Research

1 article
BREAKINGFDAMar 19, 2026

FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide

The U.S. Food and Drug Administration today approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection for weight loss and long-term maintenance of weight loss for certain adult patients.

Read ↗

Browse all IgG4-related sclerosing cholangitis news →

Specialist Network

Top 6 by expertise

View all IgG4-related sclerosing cholangitis specialists →

Quick Actions